机器人辅助根治性前列腺切除术中NeuroSAFE冰冻切片:NeuroSAFE PROOF可行性随机对照试验的围手术期与组织病理学结果
该可行性随机对照试验在2018年5月至2019年3月于英国两家中心纳入49例接受机器人辅助根治性前列腺切除术的患者,其中25例随机至NeuroSAFE组、24例至标准组。NeuroSAFE组冰冻切片与最终石蜡切片在神经血管束水平敏感度100%、特异度92.7%、AUC 0.963。NeuroSAFE组手术时间平均3小时16分钟,长于标准组的2小时4分钟,但未增加短期并发症。
要点
- NeuroSAFE冰冻切片与最终病理在神经血管束水平高度一致,敏感度100%、特异度92.7%。
- 该可行性研究支持开展已启动的充分把握度NeuroSAFE PROOF随机对照试验。
核心结论
- NeuroSAFE技术在NeuroSAFE PROOF试验中安全、可重复,且与最终病理组织学一致性优异。
- 该技术虽延长机器人辅助根治性前列腺切除术时间,但未造成短期伤害。
研究设计与样本
- 可行性随机对照试验(NCT03317990),2018年5月至2019年3月在英国两家中心纳入49例接受机器人辅助根治性前列腺切除术的患者。
- 25例随机至NeuroSAFE组(干预组),24例随机至标准组(对照组)。
- NeuroSAFE组25例患者的冰冻切片与最终石蜡切片切缘评估进行比较,两组的操作时间与并发症均前瞻性收集。
主要发现
- 按每个病理切片分析(n=250,平均每侧5个),敏感度100%、特异度99.2%、AUC 0.994(95%CI 0.985-1;P≤0.001)。
- 按神经血管束分析(n=50),敏感度100%、特异度92.7%、AUC 0.963(95%CI 0.914-1;P≤0.001)。
- NeuroSAFE组手术时间平均3小时16分钟(从切皮至离台,95%CI 3小时2分钟-3小时30分钟),标准组平均2小时4分钟(95%CI 2小时2分钟-2小时25分钟;P≤0.001)。
- NeuroSAFE组因手术时间延长未出现相关并发症。
临床怎么用
- NeuroSAFE冰冻切片可用于机器人辅助根治性前列腺切除术中实时评估神经血管束切缘,组织病理学一致性高。
局限性
- 本研究为可行性试验,样本量小(49例),主要目的是评估可行性与安全性,而非疗效。
- NeuroSAFE组仅25例患者、50个神经血管束用于组织病理学一致性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report on the methods, peri-operative outcomes and histopathological concordance between frozen and final section from the NeuroSAFE PROOF feasibility study (NCT03317990). PATIENTS AND METHODS: Between May 2018 and March 2019, 49 patients at two UK centres underwent robot-assisted radical prostatectomy (RARP). Twenty-five patient were randomized to NeuroSAFE RARP (intervention arm) and 24 to standard RARP (control arm). Frozen section was compared to final paraffin section margin assessment in the 25 patients in the NeuroSAFE arm. Operation timings and complications were collected prospectively in both arms. RESULTS: Fifty neurovascular bundles (NVBs) from 25 patients in the NeuroSAFE arm were analysed. When analysed by each pathological section (n = 250, average five per side), we noted a sensitivity of 100%, a specificity of 99.2%, and an area under the curve (AUC) of 0.994 (95% confidence interval [CI] 0.985 to 1; P ≤0.001). On an NVB basis (n = 50), sensitivity was 100%, specificity was 92.7%, and the AUC was 0.963 (95% CI 0.914 to 1; P ≤0.001). NeuroSAFE RARP lasted a mean of 3 h 16 min (knife to skin to off table, 95% CI 3 h 2 min-3 h 30 min) compared to 2 h 4 min (95% CI 2 h 2 min-2 h 25 min; P ≤0.001) for standard RARP. There was no morbidity associated with the additional length of operating time on in the NeuroSAFE arm. CONCLUSION: This feasibility study demonstrates the safety, reproducibility and excellent histopathological concordance of the NeuroSAFE technique in the NeuroSAFE PROOF trial. Although the technique increases the duration of RARP, this does not cause short-term harm. Confirmation of feasibility has led to the opening of the fully powered NeuroSAFE PROOF randomized controlled trial, which is currently under way at four sites in the UK.
引用
- Dinneen E, Haider A, Grierson J, et al. NeuroSAFE frozen section during robot-assisted radical prostatectomy: peri-operative and histopathological outcomes from the NeuroSAFE PROOF feasibility randomized controlled trial. BJU Int. 2021. PMID: 32985121. doi:10.1111/bju.15256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。